Загрузка...
Diffuse pulmonary lymphangiomatosis treated with bevacizumab
Diffuse pulmonary lymphangiomatosis (DPL) is a rare disease caused by uncontrolled lymphatic vessel proliferation resulting in respiratory dysfunction. Lymphatic vessel growth is influenced by vascular endothelial growth factor (VEGF). It has been shown that bevacizumab, a monoclonal antibody to VEG...
Сохранить в:
| Опубликовано в: : | Respirol Case Rep |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons, Ltd
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6260917/ https://ncbi.nlm.nih.gov/pubmed/30510764 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.384 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|